GSK: Cervical cancer vaccine protects for more than five years

04/17/2007 | Forbes

GlaxoSmithKline released new data showing its cervical cancer vaccine Cervarix prevents pre-cancerous lesions caused by two viruses for five and a half years. GSK has applied to U.S. and European regulators for approval of the vaccine, which would compete with Merck's Gardasil.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD